Advertisement
Singapore markets close in 2 hours 24 minutes

  • Straits Times Index

    3,260.18
    +35.01 (+1.09%)
     

  • Nikkei

    37,552.16
    +113.55 (+0.30%)
     

  • Hang Seng

    16,790.84
    +279.15 (+1.69%)
     

  • FTSE 100

    8,023.87
    +128.02 (+1.62%)
     

  • Bitcoin USD

    66,527.88
    +180.55 (+0.27%)
     

  • CMC Crypto 200

    1,402.20
    -12.56 (-0.89%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • Dow

    38,239.98
    +253.58 (+0.67%)
     

  • Nasdaq

    15,451.31
    +169.30 (+1.11%)
     

  • Gold

    2,316.80
    -29.60 (-1.26%)
     

  • Crude Oil

    83.02
    +0.17 (+0.21%)
     

  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     

  • FTSE Bursa Malaysia

    1,564.61
    +5.02 (+0.32%)
     

  • Jakarta Composite Index

    7,120.97
    +47.15 (+0.67%)
     

  • PSE Index

    6,509.16
    +65.08 (+1.01%)
     

Why BioCryst Pharmaceuticals Stock Is Skyrocketing This Week

Keith Speights, The Motley Fool
·2-min read
Why BioCryst Pharmaceuticals Stock Is Skyrocketing This Week

Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were skyrocketing 40.2% higher this week as of the market close on Thursday, according to on data from S&P Global Market Intelligence. BioCryst announced preliminary net revenue for hereditary angioedema (HAE) drug Orladeyo of $45.6 million for the fourth quarter of 2021. In addition, BioCryst stated that it has begun enrolling patients in two pivotal clinical studies evaluating its experimental oral Factor D inhibitor, BCX990, in treating rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH).

Continue reading